Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity

JAMA

Volumn 307, Issue 3, 2012, Pages 275-282

  Schmidt, Barbara ^a,b   Anderson, Peter J ^c,d   Doyle, Lex W ^c,d,e   Dewey, Deborah ^f   Grunau, Ruth E ^g,h   Asztalos, Elizabeth V ⁱ   Davis, Peter G ^d,e   Tin, Win ^j   Moddemann, Diane ^k   Solimano, Alfonso ^h   Ohlsson, Arne ⁱ   Barrington, Keith J ^l,m   Roberts, Robin S ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e ROYAL WOMEN'S HOSPITAL   (Australia)

^f UNIVERSITY OF CALGARY   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ UNIVERSITY OF TORONTO   (Canada)

^j JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^k UNIVERSITY OF MANITOBA   (Canada)

^l MCGILL UNIVERSITY   (Canada)

^m UNIVERSITY OF MONTREAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; PLACEBO; CENTRAL STIMULANT AGENT;

APNEA; ARTICLE; BEHAVIOR DISORDER; BLINDNESS; CHILD; CHILD DEATH; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GROSS MOTOR FUNCTION CLASSIFICATION SYSTEM; HEARING IMPAIRMENT; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; OUTCOME ASSESSMENT; POOR GENERAL CONDITION; PREMATURITY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SURVIVAL TIME; VERY LOW BIRTH WEIGHT; CEREBRAL PALSY; CHILD DEVELOPMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEVELOPMENTAL DISORDER; INCIDENCE; INFANT; MULTICENTER STUDY; NEWBORN; RISK; SURVIVAL; TREATMENT OUTCOME;

APNEA; BLINDNESS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBRAL PALSY; CHILD DEVELOPMENT; CHILD, PRESCHOOL; COGNITION DISORDERS; DEAFNESS; DEVELOPMENTAL DISABILITIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; MALE; ODDS RATIO; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84856020166     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.2024     Document Type: Article

References (30)

1. Abu-Shaweesh JM, Martin RJ. Neonatal apnea: what's new? Pediatr Pulmonol. 2008;43(10):937-944.
2. Henderson-Smart DJ, De Paoli AG. Methylxanthine treatment for apnoea in preterm infants. Cochrane Database Syst Rev. 2010;(12):CD000140.
3. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics. 2006;117(6):1979-1987. (Pubitemid 46071242)
4. Aranda JV, Beharry K, Valencia GB, Natarajan G, Davis J. Caffeine impact on neonatal morbidities. J Matern Fetal Neonatal Med. 2010;23(S3)(suppl 3): 20-23.
5. Schmidt B, Roberts RS, Davis P, et al Caffeine for Apnea of Prematurity Trial Group. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006; 354(20):2112-2121. (Pubitemid 43736611)
6. Schmidt B, Roberts RS, Davis P, et al Caffeine for Apnea of Prematurity Trial Group. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893-1902. (Pubitemid 350074685)
7. Dukhovny D, Lorch SA, Schmidt B, et al Caffeine for Apnea of Prematurity Trial Group. Economic evaluation of caffeine for apnea of prematurity. Pediatrics. 2011;127(1):e146-e155.
8. Hack M, Taylor HG, Drotar D, et al. Poor predictive validity of the Bayley Scales of Infant Development for cognitive function of extremely low birth weight children at school age. Pediatrics. 2005; 116(2):333-341. (Pubitemid 44161457)
9. Aylward GP. Cognitive function in preterm infants: no simple answers. JAMA. 2003;289(6): 752-753. (Pubitemid 37430371)
10. Marlow N, Wolke D, Bracewell MA, Samara M; EPICure Study Group. Neurologic and developmental disability at six years of age after extremely preterm birth. N Engl J Med. 2005;352(1):9-19. (Pubitemid 40075676)
11. Robertson CM, Watt MJ, Dinu IA. Outcomes for the extremely premature infant: what is new? and where are we going? Pediatr Neurol. 2009;40 (3):189-196.
12. Roberts G, Anderson PJ, Doyle LW; Victorian Infant Collaborative Study Group. The stability of the diagnosis of developmental disability between ages 2 and 8 in a geographic cohort of very preterm children born in 1997. Arch Dis Child. 2010;95(10): 786-790.
13. Pesce AJ, Rashkin M, Kotagal U; National Academy of Clinical Biochemistry. Standards of laboratory practice: theophylline and caffeine monitoring. Clin Chem. 1998;44(5):1124-1128. (Pubitemid 28213160)
14. Bayley N. Manual for the Bayley Scales of Infant Development. 2nd ed. San Antonio, TX: Psychological Corporation; 1993.
15. Schmidt B. Methylxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. Biol Neonate. 2005; 88(3):208-213. (Pubitemid 41433553)
16. Palisano R, Rosenbaum P, Walter S, Russell D, Wood E, Galuppi B. Development and reliability of a system to classify gross motor function in children with cerebral palsy. Dev Med Child Neurol. 1997;39 (4):214-223. (Pubitemid 27226331)
17. Psychological Corporation. Wechsler Preschool and Primary Scale of Intelligence. 3rd ed. Toronto, Canada: Psychological Corporation; 2002.
18. Achenbach TM. Manual for the Child Behavior Checklist. Burlington: University of Vermont; 2002.
19. Hille ET, den Ouden AL, Saigal S, et al. Behavioural problems in children who weigh 1000 g or less at birth in four countries. Lancet. 2001;357(9269): 1641-1643. (Pubitemid 32568235)
20. Henderson SE, Sugden DA. Movement Assessment Battery for Children (Movement ABC). Toronto, Canada: Psychological Corporation; 1992.
21. Beery KE, Buktenica NA, Beery NA. The Beery-Buktenica Developmental Test of Visual-Motor Integration (VMI). 5th ed. Parsippany, NJ: Modern Curriculum Press; 2004.
22. Centers for Disease Control and Prevention. Growth charts. http://www.cdc.gov/growthcharts /computer-programs.htm. Accessed December 17, 2010.
23. Kramer MS, Platt RW, Wen SW, et al Fetal/Infant Health Study Group of the Canadian Perinatal Surveillance System. A new and improved population-based Canadian reference for birth weight for gestational age. Pediatrics. 2001;108(2):E35.
24. Millar D, Schmidt B. Controversies surrounding xanthine therapy. Semin Neonatol. 2004;9(3): 239-244. (Pubitemid 38525028)
25. Finer NN, Higgins R, Kattwinkel J, Martin RJ. Summary proceedings from the apnea-of-prematurity group. Pediatrics. 2006;117(3 pt 2):S47-S51. (Pubitemid 46063172)
26. Msall ME. Optimizing neuromotor outcomes among very preterm, very low-birth-weight infants. JAMA. 2009;302(20):2257-2258.
27. Williams J, Lee KJ, Anderson PJ. Prevalence of motor-skill impairment in preterm children who do not develop cerebral palsy: a systematic review. Dev Med Child Neurol. 2010;52(3):232-237.
28. de Kieviet JF, Piek JP, Aarnoudse-Moens CS, Oosterlaan J. Motor development in very preterm and very low-birth-weight children from birth to adolescence: a meta-analysis. JAMA. 2009;302(20):2235-2242.
29. Ledent C, Vaugeois JM, Schiffmann SN, et al. Aggressiveness, hypoalgesia and high blood pressure in mice lacking the adenosine A2a receptor. Nature. 1997; 388(6643):674-678. (Pubitemid 27366438)
30. Johansson B, Halldner L, Dunwiddie TV, et al. Hyperalgesia, anxiety, and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc Natl Acad Sci U S A. 2001;98(16): 9407-9412. (Pubitemid 32743930)